Author reply.

Bascom Palmer Eye Institute, Department of Ophthalmology, Miami, Florida.
Ophthalmology (Impact Factor: 6.17). 07/2013; 120(7):e49-50. DOI: 10.1016/j.ophtha.2013.02.027
Source: PubMed
Download full-text


Available from: Harry W Flynn, Nov 19, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metastasis from uveal melanoma occurs almost exclusively with tumors showing chromosome 3 loss. We used multiplex ligation-dependent probe amplification (MLPA) to detect chromosome 1p, 3, 6p, 6q, 8p, and 8q abnormalities in uveal melanomas. The purpose of this study was to correlate our MLPA results with other risk factors and metastatic death. Patients were included if they had a uveal melanoma involving choroid. Correlations between baseline risk factors were analyzed using the chi-square test (without Yates's adjustment) and the Mann-Whitney test, with log-rank analysis for associations with metastatic death. The patients (194 female; 258 male) had a median age of 59.4 years and a median follow-up of 1.89 years. MLPA abnormalities occurred in a wide variety of combinations. Ten-year disease-specific mortality was 0% in 133 tumors with no chromosome 3 loss, 55% in tumors with chromosome 3 loss but no chromosome 8q gain, and 71% in 168 tumors showing combined chromosome 3 loss and 8q gain. In tumors with both these abnormalities, epithelioid melanoma cytomorphology, closed loops, and high mitotic rate correlated with poor survival as did lack of chromosome 6p gain. These results support the use of MLPA for routine clinical prognostication, especially if the genetic data are considered together with clinical and histologic risk factors. We showed a wide variety of MLPA results, which suggests that chromosomal abnormalities in uveal melanoma accumulate in a variable sequence.
    Clinical Cancer Research 10/2010; 16(24):6083-92. DOI:10.1158/1078-0432.CCR-10-2076 · 8.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Survival in choroidal melanoma was modelled using accelerated failure time models. We combined pathological, clinical and genetic data, using imputation techniques. Performance was assessed using n-fold cross-validation. Using data from 3653 patients, we generated two models; the first using clinical data only and the second using clinical and laboratory data. The c-index of discrimination was 0.75 for the clinical model and 0.79 for the laboratory model. Calibration showed good correlation between predicted and observed mortality (p-value: 0.699 for clinical model and 0.801 for laboratory model). We conclude that our model provides reasonably reliable prognosis relevant to individual patients.
    International Journal of Biomedical Engineering and Technology 01/2012; 8(1):18 - 35. DOI:10.1504/IJBET.2012.045355
  • Collaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma. . Ophthalmology 119 1596-603.